NeurologyLive - Clinical Neurology News and Neurology Expert Insights articleshttps://www.neurologylive.com/newsNeurologyLive - Clinical Neurology News and Neurology Expert Insights articles© 2026 MJH Life Sciences™ and NeurologyLive - Clinical Neurology News and Neurology Expert Insights. All rights reserved.Fri, 02 Oct 2026 02:49:55 +00005en-us14447https://www.neurologylive.com/newshttps://www.neurologylive.com/logo.webphttps://www.neurologylive.com/view/congress-passes-act-als-reauthorization-extending-research-programshttps://www.neurologylive.com/view/congress-passes-act-als-reauthorization-extending-research-programs<![CDATA[The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 extends federal support for ALS research and expanded access to investigational therapies, with additional provisions addressing clinical trial oversight and regulatory planning.]]>Thu, 01 Oct 2026 22:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/bbp-418-improves-ambulation-pulmonary-function-across-subgroups-phase-3-fortify-interim-analysis-for-lgmd2i-r9https://www.neurologylive.com/view/bbp-418-improves-ambulation-pulmonary-function-across-subgroups-phase-3-fortify-interim-analysis-for-lgmd2i-r9<![CDATA[New 12-month interim data showed functional gains with BBP-418 vs placebo, consistent benefit across genotype, age, and baseline pulmonary function subgroups, and a safety profile comparable to placebo.]]>Thu, 01 Oct 2026 19:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/phase-4-study-risdiplam-use-shows-stable-motor-function-adults-with-smahttps://www.neurologylive.com/view/phase-4-study-risdiplam-use-shows-stable-motor-function-adults-with-sma<![CDATA[Real-world 12‑month results from WeSMA, a phase 4 study, showed that oral risdiplam is well tolerated in adults with SMA, with stable motor function and consistent safety findings.]]>Thu, 01 Oct 2026 17:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/phase-4-study-evaluates-transition-from-ivig-subcutaneous-efgartigimod-cidphttps://www.neurologylive.com/view/phase-4-study-evaluates-transition-from-ivig-subcutaneous-efgartigimod-cidp<![CDATA[A phase 4 study is evaluating whether adults with chronic inflammatory demyelinating polyneuropathy can transition from intravenous immunoglobulin to subcutaneous efgartigimod PH20 without first experiencing disease worsening.]]>Thu, 01 Oct 2026 15:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/phase-4-octagon-trial-test-rapid-steroid-taper-with-ravulizumabhttps://www.neurologylive.com/view/phase-4-octagon-trial-test-rapid-steroid-taper-with-ravulizumab<![CDATA[A new phase 4 trial, OCTAGON, will test a rapid, predefined corticosteroid-tapering schedule in patients with generalized myasthenia gravis treated with ravulizumab.]]>Thu, 01 Oct 2026 12:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/petunia-study-to-track-nipocalimab-use-pregnancyhttps://www.neurologylive.com/view/petunia-study-to-track-nipocalimab-use-pregnancy<![CDATA[PETUNIA, a new global pharmacovigilance study, will track pregnancy, maternal, and infant outcomes among patients with gMG exposed to nipocalimab.]]>Thu, 01 Oct 2026 10:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/tasimelteon-advances-sleep-onset-phase-3-delayed-sleep-wake-trialhttps://www.neurologylive.com/view/tasimelteon-advances-sleep-onset-phase-3-delayed-sleep-wake-trial<![CDATA[In a pivotal phase 3 study, once-daily tasimelteon 20 mg shifted sleep onset 37.1 minutes earlier than placebo in adults with delayed sleep-wake phase disorder.]]>Wed, 30 Sep 2026 20:48:45 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/single-infusion-rese-cel-yields-meaningful-responses-off-immunomodulators-phase-1-2-reset-mg-trialhttps://www.neurologylive.com/view/single-infusion-rese-cel-yields-meaningful-responses-off-immunomodulators-phase-1-2-reset-mg-trial<![CDATA[Findings from the phase 1/2 RESET-MG trial, presented at AANEM 2026, showed that 10 of 13 patients with refractory generalized myasthenia gravis had clinically meaningful MG-ADL improvements after a single infusion of rese-cel. ]]>Wed, 30 Sep 2026 17:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/episode-176-bbp-418-changing-treatment-landscape-of-lgmdhttps://www.neurologylive.com/view/episode-176-bbp-418-changing-treatment-landscape-of-lgmd<![CDATA[Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Katherine Matthews, MD. [LISTEN TIME: 17 minutes]]]>Wed, 30 Sep 2026 17:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/fda-accepts-fenebrutinib-nda-under-priority-review-relapsing-primary-progressive-mshttps://www.neurologylive.com/view/fda-accepts-fenebrutinib-nda-under-priority-review-relapsing-primary-progressive-ms<![CDATA[The FDA accepted fenebrutinib's new drug application under priority review for relapsing and primary progressive MS, based on 3 phase 3 trials comparing the BTK inhibitor with teriflunomide and ocrelizumab.]]>Wed, 30 Sep 2026 15:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/adhere-real-study-assess-real-world-effectiveness-efgartigimod-cidphttps://www.neurologylive.com/view/adhere-real-study-assess-real-world-effectiveness-efgartigimod-cidp<![CDATA[A new study will follow adults with chronic inflammatory demyelinating polyradiculoneuropathy who start subcutaneous efgartigimod in routine practice in the US and Germany.]]>Wed, 30 Sep 2026 12:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/neurovoices-james-winkley-analyzing-phase-3-prevail-trial-gefurulimabhttps://www.neurologylive.com/view/neurovoices-james-winkley-analyzing-phase-3-prevail-trial-gefurulimab<![CDATA[The chairman of the Neurology Service Line at Baptist Health in Kentucky discussed PREVIEW trial findings for gefelorilimab in generalized myasthenia gravis, including efficacy, safety, and what the subcutaneous C5 inhibitor could offer patients if approved.]]>Wed, 30 Sep 2026 10:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/empasiprubart-phase-3-trials-compare-treatment-placebo-ivig-cidphttps://www.neurologylive.com/view/empasiprubart-phase-3-trials-compare-treatment-placebo-ivig-cidp<![CDATA[Phase 3 trials EMNERGIZE and EMVIGORATE will evaluate the efficacy and safety of intravenous empasiprubart in adults with chronic inflammatory demyelinating polyradiculoneuropathy. ]]>Tue, 29 Sep 2026 22:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/epilepsygtx-viralgen-partner-aav-gene-therapy-epy201-ahead-planned-first-human-trialhttps://www.neurologylive.com/view/epilepsygtx-viralgen-partner-aav-gene-therapy-epy201-ahead-planned-first-human-trial<![CDATA[EpilepsyGTx and Viralgen have entered a manufacturing collaboration to support development of EPY201, an investigational AAV9-based gene therapy for focal refractory epilepsy planned to enter first-in-human testing in 2027.]]>Tue, 29 Sep 2026 19:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/global-phase-3-upstream-mg-trial-telitacicept-advances-enrollment-generalized-myasthenia-gravishttps://www.neurologylive.com/view/global-phase-3-upstream-mg-trial-telitacicept-advances-enrollment-generalized-myasthenia-gravis<![CDATA[The ongoing phase 3 study is enrolling approximately 180 adults across more than 13 countries, with topline results expected in mid-2027.]]>Tue, 29 Sep 2026 17:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/zilucoplan-autoinjector-matches-bioequivalence-pre-filled-syringe-myasthenia-gravishttps://www.neurologylive.com/view/zilucoplan-autoinjector-matches-bioequivalence-pre-filled-syringe-myasthenia-gravis<![CDATA[New data from the 2026 AANEM Annual Meeting showed zilucoplan delivered via autoinjector was bioequivalent to the pre-filled syringe and was well tolerated when self-administered by patients with generalized myasthenia gravis.]]>Tue, 29 Sep 2026 15:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/rethinking-the-disease-model-etiology-over-symptomhttps://www.neurologylive.com/view/rethinking-the-disease-model-etiology-over-symptom<![CDATA[The panelists discuss the critical shift from seizure-focused management to targeting the underlying genetic etiology of Dravet syndrome, drawing on natural history data that shows developmental impairment progresses independently of seizure control.]]>Tue, 29 Sep 2026 12:05:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/evaluating-zeleciment-basivarsen-myotonic-dystrophy-type-1-phase-3-harmonia-trialhttps://www.neurologylive.com/view/evaluating-zeleciment-basivarsen-myotonic-dystrophy-type-1-phase-3-harmonia-trial<![CDATA[The phase 3 HARMONIA trial will evaluate whether a muscle- and CNS-targeted antisense conjugate improves function across multiple systems in patients with myotonic dystrophy type 1.]]>Tue, 29 Sep 2026 12:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/understanding-dravet-syndrome-the-disease-and-its-burdenhttps://www.neurologylive.com/view/understanding-dravet-syndrome-the-disease-and-its-burden<![CDATA[Three epileptologists set the stage on Dravet syndrome, exploring the biological underpinnings of the disease, the cascading burden it places on patients and families, and why this condition demands far more than seizure management.]]>Tue, 29 Sep 2026 12:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/inebilizumab-durable-benefit-musk-generalized-myasthenia-gravis-aanem-2026https://www.neurologylive.com/view/inebilizumab-durable-benefit-musk-generalized-myasthenia-gravis-aanem-2026<![CDATA[New phase 3 MINT trial analyses presented at the 2026 AANEM Annual Meeting showed inebilizumab produced sustained improvement in MuSK-positive gMG regardless of time since diagnosis.]]>Tue, 29 Sep 2026 10:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/shield-trial-advances-combination-antiviral-long-covidhttps://www.neurologylive.com/view/shield-trial-advances-combination-antiviral-long-covid<![CDATA[PridCor Therapeutics is moving its phase 2 SHIELD trial of a combination antiviral regimen toward enrollment, building on case series data showing durable symptom improvement in long COVID.]]>Mon, 28 Sep 2026 19:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/moving-needle-on-stroke-recurrence-patients-limited-access-care-eva-mistryhttps://www.neurologylive.com/view/moving-needle-on-stroke-recurrence-patients-limited-access-care-eva-mistry<![CDATA[The professor of neurology at the University of Cincinnati discussed how clinical awareness of social determinants and expanded telehealth have begun to move the needle for stroke care. [WATCH TIME: 7 minutes]]]>Mon, 28 Sep 2026 19:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/gefurulimab-cuts-hospitalizations-sustains-response-phase-3-prevail-trial-myasthenia-gravishttps://www.neurologylive.com/view/gefurulimab-cuts-hospitalizations-sustains-response-phase-3-prevail-trial-myasthenia-gravis<![CDATA[New PREVAIL trial analyses presented at the 2026 AANEM Annual Meeting showed gefurulimab reduced gMG-related hospitalizations and produced durable symptom and quality-of-life gains through one year.]]>Mon, 28 Sep 2026 17:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/fda-approves-tavapadon-for-the-treatment-of-parkinson-diseasehttps://www.neurologylive.com/view/fda-approves-tavapadon-for-the-treatment-of-parkinson-disease<![CDATA[FDA approves once-daily oral tavapadon for Parkinson disease, a first-in-class D1/D5 partial agonist that improves motor function and ON time, with key safety warnings.]]>Mon, 28 Sep 2026 12:33:56 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/survey-identifies-somnolence-risk-and-short-term-efficacy-drive-vmat2-inhibitor-selection-tardive-dyskinesia-older-adultshttps://www.neurologylive.com/view/survey-identifies-somnolence-risk-and-short-term-efficacy-drive-vmat2-inhibitor-selection-tardive-dyskinesia-older-adults<![CDATA[In a discrete choice experiment, somnolence risk and short-term efficacy were the top factors driving vesicular monoamine transporter 2 inhibitor selection for tardive dyskinesia in patients aged 55 years and older.]]>Mon, 28 Sep 2026 12:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/this-week-on-neurologylive-september-28-2026https://www.neurologylive.com/view/this-week-on-neurologylive-september-28-2026<![CDATA[Here's some of what is coming soon to NeurologyLive® this week. ]]>Mon, 28 Sep 2026 10:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/fda-extends-relutrigine-review-delays-pdufa-to-decemberhttps://www.neurologylive.com/view/fda-extends-relutrigine-review-delays-pdufa-to-december<![CDATA[The FDA extended its review of relutrigine for SCN2A- and SCN8A-related epilepsies by three months, pushing the PDUFA date to December 27, 2026.]]>Sun, 27 Sep 2026 19:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/neurologylive-brain-games-september-2026https://www.neurologylive.com/view/neurologylive-brain-games-september-2026<![CDATA[Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is clinical trial results in Alzheimer disease!]]>Sun, 27 Sep 2026 10:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/azetukalner-nda-submitted-ema-gives-approval-recommendation-ocrelizumab-phase-3-fusion-trial-meets-end-pointshttps://www.neurologylive.com/view/azetukalner-nda-submitted-ema-gives-approval-recommendation-ocrelizumab-phase-3-fusion-trial-meets-end-points<![CDATA[Neurology News Network for the week ending September 26th, 2026. [WATCH TIME: 4 minutes]]]>Sat, 26 Sep 2026 11:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articleshttps://www.neurologylive.com/view/whats-next-ataxia-pipeline-overview-investigational-therapeuticshttps://www.neurologylive.com/view/whats-next-ataxia-pipeline-overview-investigational-therapeutics<![CDATA[In recognition of International Ataxia Awareness Day, observed annually on September 25, NeurologyLive® reviews 6 investigational agents in clinical development across ataxia-related disorders.]]>Fri, 25 Sep 2026 22:00:00 GMTNeurologyLive - Clinical Neurology News and Neurology Expert InsightsusNeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles